UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA
Clinical trials for UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an immunotherapy boost help fight stomach cancer?
Disease control Recruiting nowThis clinical trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or esophageal cancer live longer. The study includes 224 adults whose cancer has a specific marker (PD-L1 CPS…
Matched conditions: UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
New chemo combo tested to extend life in Hard-to-Treat stomach and esophageal cancers
Disease control Recruiting nowThis study tests whether a stronger chemotherapy mix (mFOLFIRINOX) works better than the standard mix (FOLFOX) for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. Some participants also receive the immunotherapy dru…
Matched conditions: UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could a heart drug boost cancer treatment? new trial tests propranolol with chemo and immunotherapy
Disease control Recruiting nowThis phase 2 trial is testing whether adding propranolol, a common beta-blocker used for heart conditions, to standard chemotherapy and pembrolizumab (an immunotherapy) can improve treatment response in people with advanced esophageal or gastroesophageal junction cancer that cann…
Matched conditions: UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC